Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357395 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01357395 is a Phase 2 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT01357395, a Phase 2 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and potential benefit of combination amuvatinib with standard of care chemotherapy treatment (platinum and etoposide) in small cell lung cancer (SCLC) subjects.
Interventions
- DRUG Amuvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357395
The ClinicalTrials.gov registry entry for NCT01357395 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amuvatinib is the first listed.
NCT01357395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01357395 about?
NCT01357395 is a clinical study titled "A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer". The purpose of the study is to evaluate the safety and potential benefit of combination amuvatinib with standard of care chemotherapy treatment (platinum and etoposide) in small cell lung cancer (SCLC) subjects.
What is the current status of trial NCT01357395?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2011-05. Estimated completion is 2012-05-28.
What interventions are being tested in trial NCT01357395?
The interventions under investigation include: Amuvatinib (DRUG).
Who is sponsoring clinical trial NCT01357395?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.